Found 1 Presentation For Request "991P"
991P - EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)
- Anna Kron (Köln, Germany)
Abstract
Background
About 4% of all
Methods
We analyzed co-occurring mutations in patients with
Results
Real-world-data (RWD) of 159 advanced NSCLC patients with
Conclusions
Regardless of subtype,
Legal entity responsible for the study
Universitätsklinikum Köln for the Network Genomic Medicine (NGM).
Funding
Conducted by Universitätsklinikum Köln, partly funded by Janssen-Cilag GmbH.
Disclosure
M. Scheffler: Financial Interests, Personal, Invited Speaker: Amgen, Boehringer Ingelheim, Takeda, Pfizer, Roche, Sanofi-Aventis, Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Amgen, Boehringer Ingelheim, Roche, Novartis, Takeda, Pfizer; Financial Interests, Personal, Expert Testimony: Amgen, Pfizer, Amgen, Takeda; Financial Interests, Institutional, Invited Speaker: Dracen Pharmaceuticals, Amgen, Dracen, Siemens Healthineers; Non-Financial Interests, Advisory Role, Patient advocacy: zielgenau e. V., YesWeCan(cer); Non-Financial Interests, Principal Investigator, YouTube channel for patients: OncoEducation. F. Kron: Financial Interests, Personal, Ownership Interest: Vitis Healthcare Group. S. Loges: Financial Interests, Personal, Invited Speaker: BerGenBio AS, BMS, Eli Lilly, Boehringer Ingelheim, Roche Pharma, Medac GmbH, Sanofi-Aventis, Novartis, AstraZeneca, Pfizer, Takeda, Amgen, Janssen, Merck; Financial Interests, Personal, Advisory Board: BerGenBio AS, BMS, Eli Lilly, Boehringer Ingelheim, Roche Pharma, Sanofi-Aventis, Novartis, AstraZeneca, Pfizer, Takeda, Amgen; Financial Interests, Institutional, Invited Speaker: BerGenBio AS; Financial Interests, Institutional, Research Grant: BMS, Eli Lilly, Roche Pharma, ADC Therapeutics; Non-Financial Interests, Member: DGHO, ASCO, AIO. J. Wolf: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Ignyta, Janssen, Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda; Financial Interests, Personal, Invited Speaker: Bayer, Chugai; Financial Interests, Institutional, Research Grant: BMS, Janssen, Novartis, Pfizer. All other authors have declared no conflicts of interest.